Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 64Cu-PSMA-I&T PET/CT Staging in High-risk Prostate Cancer in Japan
jRCT2031250225Phase 2Active, not recruiting
- Sponsor
- PDRadiopharma Inc.
- Start
- Sep 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copper Cu 64 PSMA I&T in prostate cancer (PCa), sponsored by PDRadiopharma Inc. Primary endpoint: Sensitivity and specificity of R-241B PET/CT for pelvic lymph node metastases. Started Sep 2025; status: active, not recruiting.
02
Drugs
copper Cu 64 PSMA I&T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031250225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250225.